Veracyte Inc. (VCYT)
NASDAQ: VCYT
· Real-Time Price · USD
26.35
-0.47 (-1.75%)
At close: Jun 20, 2025, 3:59 PM
26.70
1.33%
Pre-market: Jun 23, 2025, 05:28 AM EDT
-1.75% (1D)
| Bid | 25.52 |
| Market Cap | 2.06B |
| Revenue (ttm) | 463.39M |
| Net Income (ttm) | 33.05M |
| EPS (ttm) | 0.42 |
| PE Ratio (ttm) | 62.74 |
| Forward PE | 37.25 |
| Analyst | Buy |
| Ask | 27.7 |
| Volume | 574,521 |
| Avg. Volume (20D) | 1,016,888 |
| Open | 27.06 |
| Previous Close | 26.82 |
| Day's Range | 26.15 - 27.06 |
| 52-Week Range | 19.73 - 47.32 |
| Beta | 2.10 |
About VCYT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VCYT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VCYT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Veracyte Inc. is scheduled to release its earnings on Aug 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+0.46%
Veracyte shares are trading lower. The company rep...
Unlock content with
Pro Subscription
7 months ago
+2.05%
Veracyte shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance. Needham and UBS maintained Buy ratings and raised their respective price targets on the stock.
1 month ago · businesswire.com
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate CancerSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer.
